Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management

Sandeep K. Krishnan, MD, Norman E. Lepor, MD, FACC, FAHA, FSCAI
Cedars-Sinai Heart Institute, Los Angeles, CA

Hyperkalemia is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and increased mortality. Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist. Hyperkalemia is likely to become more common clinically because angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are increasingly being used in higher doses and are thought to confer cardiovascular and renal protection. Until recently, options for treating hyperkalemia were limited to the use of thiazide and loop diuretics and sodium polystyrene sulfonate. Newer options such as sodium zirconium cyclosilicate will allow for the safe and effective treatment of hyperkalemia while maintaining patients on prescribed renin-angiotensin-aldosterone system inhibitors.


© 2016 MedReviews®, LLC

KEY WORDS

- Hyperkalemia
- Potassium
- Chronic kidney disease
- Congestive heart failure
- Patiromer
- Sodium zirconium cyclosilicate

Potassium is one of the most abundant ions in the body (50-75 mmol/kg body weight) and approximately 98% of potassium is located intracellularly (~ 140 mmol/L). Potassium homeostasis is a very important aspect of electrolyte regulation; hyperkalemia (defined as a serum potassium level > 5 mmol/L) is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and increased mortality. This is, in large part, due to the increasing use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in clinical practice as
Antihypertensive agents, heart failure treatments, and to decrease cardiovascular events in a large subset of high-risk patients.

The prevalence of hyperkalemia in the general population is unknown and difficult to quantify. However, it is present in up to 10% of hospitalized patients, depending on how hyperkalemia is defined. Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist. The incidence of hyperkalemia with renin-angiotensin-aldosterone system (RAAS) inhibitor monotherapy is low (≤ 2%) in patients without predisposing factors, but increases with dual RAAS inhibitor use (5%) and in patients with risk factors such as chronic kidney disease (CKD), congestive heart failure (CHF), and/or diabetes (5%–10%). And because one third to one half of patients with CHF have CKD, in actual practice a large proportion of patients being treated with these drugs are at increased risk for hyperkalemia.

Predisposing factors for hyperkalemia are numerous. Hyperkalemia may result from impaired potassium distribution between intracellular and extracellular spaces, increased potassium intake, and/or conditions that reduce potassium excretion, including CKD, hypertension, diabetes, and chronic CHF. Additionally, various drugs, including those taken for CKD and CHF, can produce hyperkalemia in up to 88% of hospitalized patients by interfering with normal potassium regulation.

Drug mechanisms leading to hyperkalemia include those that decrease aldosterone synthesis/action (ACE inhibitors, ARBs, heparins, mineralocorticoid receptor antagonists); those that suppress renin release (nonsteroidal anti-inflammatory drugs [NSAIDs], cyclosporine, tacrolimus); those that inhibit sodium-potassium adenosine triphosphatase, including β-blockers and digoxin (as well as digitalis-like remedies); drugs that decrease adrenal steroid synthesis (azole antifungals); antibiotics such as penicillin G, which increase potassium intake into cells (several herbal supplements fall into this category as well, including alfalfa, dandelion, etc); those that impair renal potassium secretion (amiloride, pentamidine, triamterene, trimethoprim); and drugs that shift potassium into the extracellular space (amino acids, aminocaproic acid, succinylcholine). The risk of hyperkalemia with the use of the aforementioned drugs increases substantially when the glomerular filtration rate is < 30 mL/min.

In normal physiology, potassium is freely filtered by the glomerulus. Most of this filtered potassium is reabsorbed in the proximal tubule and loop of Henle, with only 10% of the filtered load reaching the distal nephron. In addition to this small amount of potassium, which is filtered, potassium is also secreted into urine in the collecting duct. Potassium secretion in this segment is regulated and varies according to physiologic needs. The two most important physiologic determinants of potassium excretion are the serum aldosterone concentration and the delivery of sodium to the distal nephron.

Aldosterone secretion is influenced by potassium concentration in the plasma and the renin-angiotensin system. The juxtaglomerular cells in the afferent arteriole secrete renin when renal perfusion pressure is low (hypovolemia, CHF, cirrhosis). Renin then acts on angiotensinogen to form angiotensin I, which is then converted to angiotensin II by ACE. Angiotensin II stimulates the release of aldosterone from the zona glomerulosa in the adrenal gland. Plasma potassium also has a direct stimulatory effect on aldosterone secretion. The stimulatory effects of angiotensin II and potassium on the release of aldosterone appear to be synergistic because the presence of one factor increases the response to the other. This interaction between potassium and angiotensin II involves the activation of a local intra-adrenal renin-angiotensin system.

The most common method of drug-induced hyperkalemia results from ACE inhibition and ARB use, which impair urinary potassium excretion by interfering with the stimulatory effect of angiotensin II on aldosterone secretion in the adrenal gland. ACE inhibition blocks the formation of angiotensin II, whereas ARBs prevent angiotensin II from binding to its adrenal receptor.
Additionally, these drugs may interfere with the angiotensin II that is generated locally within the adrenal zona glomerulosa.

Clinicians are occasionally confronted with the finding of an elevated serum or plasma potassium level in an otherwise healthy person. Such an abnormality may herald the presence of occult mineralocorticoid deficiency or a defect in renal tubular transport.23 Alternatively, it may represent pseudohyperkalemia—a condition caused by the release of potassium from formed elements in the blood in patients with severe leukocytosis or thrombocytosis.24-23 There are not extensive systemic data on pseudohyperkalemia but there are multiple case reports in the literature describing pseudohyperkalemia in various clinical scenarios including repeated fist clenching during venipuncture, thrombocytosis, and extreme leukocytosis, to name a few. Pseudohyperkalemia has also been linked to traumatic transport of blood samples in hospital pneumatic tube transport systems. Whatever the cause, pseudohyperkalemia should be recognized as a spurious increase of potassium level and should not be treated, as it usually does not have the life-threatening consequences of true hyperkalemia.

The goal of managing non-emergent hyperkalemia is to prevent the progression to the more life-threatening emergent state and treat the underlying causes of potassium imbalance. Eliminating modifiable causes, including a high potassium intake in foods or with supplements or nonessential medications likely to predispose to hyperkalemia, is a first step (Table 1). A normal amount of potassium in a typical diet of a healthy American is approximately 3500 to 4500 mg/d. A potassium-restricted diet typically includes approximately 2000 mg/d.

Carefully reviewing a patient’s updated and comprehensive list of all medications and supplements will help to avoid inadvertent use of potassium supplements and removing those medications that can adversely affect potassium balance (Table 2). According to the US Department of Agriculture, herbs including alfalfa, noni, and dandelion, and herbs including chervil, coriander, parsley, tarragon, turmeric, basil, and dill weed are high in potassium. Until recently, little had changed regarding the treatment of nonemergent hyperkalemia. Approaches to preventing and treating mild hyperkalemia include initiating a low-potassium diet (< 2000 mg/d), and avoiding the use of potassium supplements, NSAIDs and cyclooxygenase-2 inhibitors. Use of RAAS inhibitors, including direct renin inhibitors, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists, are all associated with an increased risk of hyperkalemia, especially in those most in need of these treatments (those with CKD, heart failure, and diabetes). It is not infrequent that the development of hyperkalemia can interfere with their being utilized for their cardiac and renal protective effects in patients being treated for hypertension and CHF. For treatment of hypertension, ACE inhibitors and ARBs are accorded top-tier recommendations for use in patients with known cardiac and vascular disease and diabetes. In those with heart failure with reduced ejection fraction, blockade of the RAAS has life-saving and quality-of-life (QoL)-enhancing effects and are critical components of national societal guideline recommendations. In an ambulatory practice, ACE inhibitor/ARB therapy contributed to hyperkalemia in up to 10% of patients and has been implicated in hyperkalemia observed in heart failure clinical trials.

In the recently reported Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF)
The largest reservoir of potassium is in the large intestine, where most of the sodium-potassium exchange takes place, leading to potassium excretion in the stool. Because of the time needed to transit to the colon, it may take hours to days for a potassium-reducing effect to occur with sodium polystyrene sulfonate (Kayexalate®; Covis Pharmaceuticals, Inc., Cary, NC). By replacing potassium with sodium, sodium polystyrene sulfonate causes a sodium load; therefore, caution is needed when using.

In the past, options for treating hyperkalemia that does not correct with conservative measures were limited to the use of diuretics (thiazide and loop diuretics) and the sodium-potassium exchange resin, sodium polystyrene sulfonate. Unfortunately, diuretics can predispose patients to prerenal azotemia and other complications. Sodium polystyrene sulfonate was introduced over 50 years ago as a treatment for hyperkalemia based on very limited data. As it passes along the intestine, sodium ions are released and exchanged for potassium ions. The largest reservoir of potassium is in the large intestine, where most of the sodium-potassium exchange takes place, leading to potassium excretion in the stool. Because of the time needed to transit to the colon, it may take hours to days for a potassium-reducing effect to occur with sodium polystyrene sulfonate (Kayexalate®, Covis Pharmaceuticals, Inc., Cary, NC). By replacing potassium with sodium, sodium polystyrene sulfonate causes a sodium load; therefore, caution is needed when using.

In the past, options for treating hyperkalemia that does not correct with conservative measures were limited to the use of diuretics (thiazide and loop diuretics) and the sodium-potassium exchange resin, sodium polystyrene sulfonate. Unfortunately, diuretics can predispose patients to prerenal azotemia and other complications. Sodium polystyrene sulfonate was introduced over 50 years ago as a treatment for hyperkalemia based on very limited data. As it passes along the intestine, sodium ions are released and exchanged for potassium ions. The largest reservoir of potassium is in the large intestine, where most of the sodium-potassium exchange takes place, leading to potassium excretion in the stool. Because of the time needed to transit to the colon, it may take hours to days for a potassium-reducing effect to occur with sodium polystyrene sulfonate (Kayexalate®, Covis Pharmaceuticals, Inc., Cary, NC). By replacing potassium with sodium, sodium polystyrene sulfonate causes a sodium load; therefore, caution is needed when using.
in patients with severe CHF, severe hypertension, and edema. Because the cation exchange is not specific to potassium and can lead to inadvertent losses of magnesium and calcium, monitoring electrolyte levels is recommended. The only clinical data supporting the use of sodium polystyrene sulfonate are from one retrospective, uncontrolled analysis. Sodium polystyrene sulfonate is contraindicated in patients with obstructive bowel disease. Cases of colonic necrosis have been reported and are probably related to the large dose of sorbitol associated with its use, leading to a black box warning. Sodium polystyrene sulfonate use is associated with a variety of shortcomings, including the high dose of sorbitol leading to gastrointestinal (GI) intolerance, sodium loading, and the resultant volume overload, making it a poor candidate for the chronic treatment of hyperkalemia.

**Patiromer**

Patiromer is indicated for the treatment of hyperkalemia and is a recent entrant into the marketplace. It is not to be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. It is a nonabsorbed, cation exchange polymer that contains a calcium-sorbitol counter-ion. Patiromer increases fecal potassium excretion by binding potassium in the GI tract, leading to greater excretion of potassium, thereby lowering serum levels. Its safety and effectiveness were demonstrated in a series of modest-sized clinical trials (Table 3). The efficacy and safety of patiromer were studied in two key studies, the Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL-HK) and Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN).

The OPAL-HK study was a single-blind randomized trial of 243 hyperkalemic patients with CKD on stable doses of at least one RAAS inhibitor. Subjects with potassium levels of 5.1 to 5.5 mEq/L received a starting daily dose of 8.4 g of patiromer and those with levels of 5.5 to 6.5 mEq/L received 16.8 g of patiromer per day. Dose titrations were designed to maintain potassium levels between 3.8 to 5.1 mEq/L. The primary endpoint was the mean change in serum potassium levels from baseline to week 4, which was $-0.65$ mEq/L in subjects treated with 8.4 g patiromer per day (total daily dose), $-1.23$ mEq/L in patients treated with 16.8 g patiromer per day (total daily dose), and $-1.01$ mEq/L in the overall population.

The AMETHYST-DN trial was a 52-week open-label trial of 304 hyperkalemic patients with type 2 diabetes and CKD on a RAAS inhibitor. Patients with a baseline serum potassium of $>5.0$ to 5.5 mEq/L or baseline serum potassium of $>5.5$ to 6.0 mEq/L were randomized to receive one of three starting doses.

Similar to sodium polystyrene sulfonate, patiromer contains sorbitol, but at a much lower exposure. Because patiromer can bind to other orally administered agents, leading to a potential reduction of their bioavailability, a black box warning mandates that other medicines be administered either 6 hours before or after taking patiromer. This 6-hour timeframe may affect compliance in patients taking medications at different times of the day. Use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal postoperative bowel motility disorder, as it may be ineffective and may worsen GI conditions.

Because patiromer can also bind to magnesium, leading to increased excretion, and cause hypomagnesemia, magnesium levels should be monitored regularly. The most common adverse reactions of patiromer include constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, and flatulence.

**Sodium Zirconium Cyclosilicate (ZS-9)**

Sodium zirconium cyclosilicate is a highly selective cation exchanger that entraps potassium in the intestinal tract in exchange for sodium and hydrogen that is pending US Food and Drug Administration approval. Cyclosilicate is not a polymer, as is the case with sodium polystyrene sulfate and patiromer, nor is it delivered with sorbitol; it is a crystal that is highly selective, capturing only potassium and ammonium ions. It was engineered to have a high-capacity, highly selective crystalline lattice that entraps potassium cations over other diverant cations such as calcium or magnesium. As a result of sodium zirconium cyclosilicate binding the ammonium ion is a net loss of acid, blood urea nitrogen, and elevation of serum bicarbonate levels, which may be favorable in patients with CKD who often have a relative metabolic acidosis. A robust clinical trial program has evaluated the safety and efficacy of sodium zirconium cyclosilicate.
**TABLE 3**

<table>
<thead>
<tr>
<th>Study</th>
<th>Clinical Trial</th>
<th>Study Design</th>
<th>Participants</th>
<th>Endpoints</th>
<th>Baseline</th>
<th>Patiromer Therapy vs Placebo Reduction of K (&lt; 96 h)</th>
<th>Patiromer Therapy vs Placebo Reduction of K (&gt; 96 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data on file; Relypsa, Inc., Redwood City, CA</td>
<td>RLY5016-101</td>
<td>Phase 1 prospective randomized double-blind, placebo-controlled trial</td>
<td>Healthy volunteers n = 33 (25/8)*</td>
<td>Safety and tolerability, urinary and fecal patiromer excretion</td>
<td>No change</td>
<td>Significant dose-dependent increase in fecal potassium excretion and decrease in urinary potassium excretion at doses of 15-60 g/d compared with placebo</td>
<td></td>
</tr>
<tr>
<td>Data on file; Relypsa, Inc., Redwood City, CA</td>
<td>RLY5016-102</td>
<td>Phase 1 open-label trial</td>
<td>n = 12 (12/0)*</td>
<td>Pharmacologic activity/safety</td>
<td>Not placebo controlled</td>
<td>Significant increase in fecal potassium excretion and a concomitant decrease in urinary potassium excretion across the QD/BID/TID dosing regimen</td>
<td></td>
</tr>
<tr>
<td>Data on file; Relypsa, Inc., Redwood City, CA</td>
<td>RLY5016-103</td>
<td>Phase 1 onset-of-action trial</td>
<td>Pts with CKD and hyperkalemia n = 15 (15/0)*</td>
<td>Time to onset of potassium-lowering action</td>
<td>Not placebo controlled</td>
<td>First statistically significant change at 7 h</td>
<td></td>
</tr>
<tr>
<td>Data on file; Relypsa, Inc., Redwood City, CA</td>
<td>RLY5016-201</td>
<td>Phase 2a proof-of-concept trial</td>
<td>Patients with hyperkalemia receiving hemodialysis n = 6 (6/0)*</td>
<td>Efficacy/safety of a fixed dose of patiromer</td>
<td>K mEq/L ≥ 5.5</td>
<td>Not placebo controlled</td>
<td></td>
</tr>
<tr>
<td>Pitt B et al</td>
<td>RLY5016-202 PEARL-HF (NCT 00369439)</td>
<td>Phase 2 prevention trial (a prospective randomized, double-blind, placebo-controlled trial)</td>
<td>Patients with HF receiving a RAAS inhibitor (ACE inhibitors, β-blockers, ARBs) or Spiro (25-50 mg/d) therapy n = 105 (56/49)*</td>
<td>Efficacy/safety in preventing hyperkalemia</td>
<td>K 4.7 mEq/L for patiromer and placebo</td>
<td>15 g/d patiromer (n = 55) or placebo (n = 48); BID for 4 wk; patiromer → reduction in K at 24 and 72 h; placebo → increase in K at 24 and 72 h</td>
<td>15 g/d patiromer or placebo, BID for 4 wk: Patiromer → K - 0.225 mEq/L relative to baseline at d 28; Placebo → K + 0.23 mEq/L relative to baseline at d 28; Patients with HF were able to increase dose of Spiro compared with patients on placebo</td>
</tr>
</tbody>
</table>

**References:**

1. Pitt B et al. PEARL-HF (NCT 00369439) Phase 2 prevention trial (a prospective randomized, double-blind, placebo-controlled trial). 

**Note:**

* N refers to the number of participants.
<table>
<thead>
<tr>
<th>Study Authors</th>
<th>Trial Code</th>
<th>Study Design</th>
<th>Eligibility</th>
<th>Endpoints</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamargo J et al.</td>
<td>RLY5016-204</td>
<td>Phase 2 prevention trial (an open-label single-arm trial)</td>
<td>HF patients with CKD treated with a RAAS inhibitor (ACE inhibitors, ARBs, β-blockers), n = 63 (63/0)</td>
<td>AU Efficacy/safety of a titration regimen in preventing hyperkalemia</td>
<td>AU At the end of 8 wk, 91% of patients → 3.5–5.5 mEq/L; 84% of patients → 4.0–5.1 mEq/L</td>
</tr>
<tr>
<td>Tamargo J et al.</td>
<td>RLY5016-205</td>
<td>Phase 2b treatment trial (an open-label, randomized, dose-ranging trial)</td>
<td>Hypertension patients with diabetic nephropathy treated with ACE inhibitors and/or ARBs, with or without Spironolactone, n = 306 (306/0)</td>
<td>AU Efficacy/safety in treating hyperkalemia, determination of starting dose and long-term safety in chronic treatment</td>
<td>AU The primary outcomes were the changes in K from baseline to the end of the study, but results were not published</td>
</tr>
<tr>
<td>Weir MR et al.</td>
<td>OPAL-HK</td>
<td>A 2-part phase 3 trial: Part A (a single-blind phase); Part B (a placebo-controlled, randomized, withdrawal phase)</td>
<td>Patients with hyperkalemia, CKD, HF receiving RAAS inhibitor therapy</td>
<td>Part A: efficacy/safety of patiromer, Part B: effect of withdrawing patiromer on control of serum potassium levels, to assess whether chronic treatment with patiromer prevents recurrence of hyperkalemia, to provide placebo-controlled safety data</td>
<td>Hyperkalemia (K 5.1 – 6.5 mEq/L)</td>
</tr>
<tr>
<td></td>
<td>RLY5016-301</td>
<td></td>
<td></td>
<td></td>
<td>Part A: initial treatment phase (n = 237) 4.2 g and 8.2 g patiromer for patients with K 5.1 – 6.5 mEq/L BID for 4 wk; 8.2 g patiromer for patients with K 5.5 – 6.5 mEq/L BID for 4 wk; patiromer → K → 1.01 mEq/L from baseline to week 4; K → 0.65 mEq/L for mild hyperkalemia, K → 1.23 mEq/L for moderate-severe hyperkalemia. Part B: randomized withdrawal phase (n = 107) Continue patiromer (8 wk) → K 0 mEq/L 8 wk-placebo → K 0.72 mEq/L</td>
</tr>
<tr>
<td></td>
<td>NCT 01810939</td>
<td></td>
<td></td>
<td></td>
<td>In subgroup analyses, patients from EE sites had greater mean reductions in K (−1.15 vs 0.75 mEq/L; P &lt; .001) and a greater percentage achieved normokalemia during the treatment phase than patients from EU and US sites; in the withdrawal phase, the difference in median change from baseline in K was greater in the EU and US patients than EE patients (1.39 vs 0.52 mEq/L)</td>
</tr>
</tbody>
</table>

*Information abstracted from multiple sources.*

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AU, awaiting update; BID, twice daily; CKD, chronic kidney disease; EE, Eastern Europe; EU, European Union; HF, heart failure; K, potassium; QD, daily; RAAS, renin-angiotensin-aldosterone system; Spironolactone; TID, three times daily; US, United States.

Reprinted with permission from McCullough PA et al. Rev Cardiovasc Med. 2015;16:140-155. © 2015 MedReviews®, LLC. All rights reserved.
### Table 4
Clinical Studies Using Sodium Zirconium Cyclosilicate (ZS-9) to Reduce Serum Potassium Levels

<table>
<thead>
<tr>
<th>Study</th>
<th>Clinical Trial</th>
<th>Study Design</th>
<th>Participants</th>
<th>Endpoints</th>
<th>Baseline</th>
<th>ZS-9 Therapy vs Placebo and Reduction of K (&lt; 96 h)</th>
<th>ZS-9 Therapy vs Placebo and Reduction of K (&gt; 96 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ash SR et al, Singh B</td>
<td>Phase II trial</td>
<td>Prospective, randomized, double-blind, placebo-controlled study</td>
<td>Patients with hyperkalemia (K ≥ 5.6 mEq/L, eGFR 30-60 mL/min/1.73 m², CKD on RAAS inhibitor therapy (n = 90))</td>
<td>Rate of change in serum potassium from baseline over 48 h</td>
<td>K 5.6 mEq/L</td>
<td>ZS-9: 0.3, 3, or 10 g, TID for ≥ 2 d; at 3 and 10 g, ZS-9 produced a rapid decrease in K over the first 48 h; at 10 g, mean rate of decline in K was −0.68 mEq/L and the maximum K was −0.92 mEq/L</td>
<td>None</td>
</tr>
<tr>
<td>Packham DK et al</td>
<td>First phase III trial</td>
<td>Two-part, multicenter, randomized, double-blind, placebo-controlled trial</td>
<td>Patients with hyperkalemia, regardless of etiology (CKD, DM, HF) on RAAS inhibitor therapy (n = 753)</td>
<td>Primary: rate of change in serum potassium from baseline to 48 h</td>
<td>Acute phase: K 5.3 mEq/L</td>
<td>48-h induction phase (K: 3.5-5.0 mEq/L)</td>
<td>ZS-9: 1.25 g (n = 154) → K 5.1 mEq/L (−0.30) ZS-9: 2.5 g (n = 141) → K 4.9 mEq/L (−0.46) ZS-9: 5 g (n = 157) → K 4.8 mEq/L (−0.54) ZS-9: 10 g (n = 143) → K 4.6 mEq/L (−0.73) Placebo (n = 158) → K 5.0 mEq/L (−0.25) TID for 48 h</td>
</tr>
<tr>
<td>Kosiborod M et al, El-Shahaway</td>
<td>Ongoing phase III trial</td>
<td>HARMONIZE trial: multicenter, randomized, double-blind, placebo-controlled trial</td>
<td>Patients with hyperkalemia, regardless of etiology (CKD, DM, HF) on RAAS inhibitor therapy (n = 258)</td>
<td>Primary: comparison of mean potassium from day 8 to day 28</td>
<td>K 5.6 mEq/L</td>
<td>Open-label induction phase ZS-9: 10 g (n = 237) → K 4.5 mEq/L (normal K 3.5-5.0 mEq/L) TID for 48 h</td>
<td>Double-blind randomized withdrawal phase (mean K &lt; 5.18 mEq/L) QD for 28 d ZS-9: 5 g (n = 45) → K 4.8 mEq/L ZS-9: 10 g (n = 51) → K 4.5 mEq/L ZS-9: 15 g (n = 56) → K 4.4 mEq/L Placebo (n = 85) → K 5.1 mEq/L 12-mo extension ZS-9: 10 g/d</td>
</tr>
<tr>
<td>Tamargo J et al</td>
<td>Planned phase III trial</td>
<td>Open-label safety exposure study</td>
<td>Patients with hyperkalemia (&gt; 5.0 mEq/L) regardless of etiology (n = 600)</td>
<td>Primary: long-term safety and tolerability</td>
<td>Secondary: proportion of patients normokalemic during induction phase and during 12-mo period</td>
<td>48-to 72-h open-label acute phase ZS-9: 10 g, TID for 48-72 h</td>
<td>12-mo maintenance phase ZS-9: 10 g, QD during 1 y (5-g dose titration if needed)</td>
</tr>
</tbody>
</table>

ZS-9 (ZS Pharma, Inc., Coppell, TX). CHF, congestive heart failure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; DM, diabetes; HARMONIZE, Hyperkalemia Randomized Intervention Multi-dose ZS-9 Maintenance; RAAS, renin-angiotensin aldosterone system; TID, three times daily. Reprinted with permission from McCullough PA et al. Rev Cardiovasc Med. 2015;16:140-155. © 2015 MedReviews LLC. All rights reserved.
sodium zirconium cyclosilicate in treating hyperkalemia in a number of clinical scenarios (Table 4).

The clinical trial program for sodium zirconium cyclosilicate includes ZS003, the multicenter, two-phase, multidose, prospective, randomized, double-blind placebo-controlled study of 753 patients with mild to moderate hyperkalemia (potassium levels of 5.0-6.5 mEq/L), including patients with CKD, heart failure, and diabetes who are on ACE inhibitors, ARBs, or mineralocorticoid antagonists. Treatment included four different doses of sodium zirconium cyclosilicate (1.25 g, 2.5 g, 5 g, and 10 g) or placebo given three times daily for the initial 48-hour acute phase (Figure 1). Patients who became normokalemic at 48 hours were then randomly assigned on day 3 to receive either sodium zirconium cyclosilicate or placebo once daily for the next 12 days followed by a 7-day follow-up phase.

The primary endpoint was the rate of change of potassium from baseline throughout the 48-hour acute phase. At 48 hours the mean reductions for the four doses tested was 0.46 mEq/L in the 2.5-g group, 0.54 mEq/L in the 5.0-g group, and 0.73 mEq/L in the 10-g group (Figure 2). At 1 hour following the first 10-g dose, a potassium level reduction of 0.11 mEq/L was observed. The more rapid reduction of potassium levels observed with sodium zirconium cyclosilicate than with other agents indicates that the potassium-binding effect starts higher in the GI tract, perhaps in the stomach or small bowel.

In the phase 3, multicenter, double-blind, placebo-controlled Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance (HARMONIZE) trial, 258 ambulatory outpatients with a potassium concentration > 5.1 mEq/L at baseline received 10 g of sodium zirconium cyclosilicate three times daily during an initial 48-hour open-label phase. Patients achieving normokalemia (3.5-5.0 mEq/L) were then randomized to one of three daily doses of sodium zirconium cyclosilicate.
Acute and Chronic Cardiovascular Effects of Hyperkalemia continued

(5 g, 10 g, or 15 g) or placebo for 28 days. Potassium was significantly reduced by 0.2 mEq/L at 1 hour following the first 10-g dose from baseline, with reductions at 2 and 4 hours after the first dose of 0.4 mEq/L and 0.5 mEq/L, respectively. At 24 and 48 hours postdose, reductions of potassium were 0.7 mEq/L and 1.1 mEq/L, respectively. Median time to normokalemia was 2.2 hours. The primary endpoint was a comparison of mean serum potassium levels among the different doses and placebo. Patients receiving 5 g, 10 g, or 15 g of sodium zirconium cyclosilicate were maintained at 4.8, 4.5, and 4.4 mEq/L versus 5.1 mEq/L for placebo patients (Figure 3). Of importance was that the potassium-lowering effect and maintenance of normokalemia occurred in patients with CKD, heart failure, and diabetes without the need to remove them from their RAAS inhibitor treatment. There was no difference from placebo in GI adverse events, with no observed increase in body weight, blood pressure, or urinary excretion. There was an increase in the incidence of edema at the 10- and 15-g doses. A comparison of the mechanism of action, efficacy, and safety of sodium zirconium cyclosilicate and patiromer are provided in Table 5.

Conclusions

Hyperkalemia is a common problem observed in both the acute care and chronic ambulatory care settings by primary care practitioners, cardiologists, nephrologists, and endocrinologists. It is especially seen among patients with diabetes, heart failure, and CKD who are treated with the renal and cardio-protective RAAS inhibitors. Until recently, the treatment of hyperkalemia was limited to discontinuation of these important and


### TABLE 5

Comparison of Sodium Zirconium Cyclosilicate and Patiromer Sorbitex Calcium

<table>
<thead>
<tr>
<th>Mechanism and Administration</th>
<th>Sodium Zirconium Cyclosilicate</th>
<th>Patiromer Sorbitex Calcium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism of action</td>
<td>Inorganic crystal → selective potassium trap</td>
<td>Organic polymer → nonspecific binding of cations</td>
</tr>
<tr>
<td>Site potassium binding</td>
<td>Entire GI tract</td>
<td>Colon</td>
</tr>
<tr>
<td>Administration</td>
<td>Once daily</td>
<td>Twice daily</td>
</tr>
<tr>
<td>Daily drug total (g)</td>
<td>5-10</td>
<td>21-35</td>
</tr>
<tr>
<td>Volume expansion</td>
<td>None</td>
<td>Swelling (H₂O absorbed)</td>
</tr>
<tr>
<td>Storage</td>
<td>Room temperature</td>
<td>2-8°C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Efficacy</th>
<th>Sodium Zirconium Cyclosilicate</th>
<th>Patiromer Sorbitex Calcium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time of Onset (h)</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>@ 4 h [baseline potassium &gt; 5.5 (mEq/L)]</td>
<td>-0.5</td>
<td>-0.14</td>
</tr>
<tr>
<td>Median time to normalization (h)</td>
<td>2.2</td>
<td>&gt; 48 (estimated 1 wk)</td>
</tr>
<tr>
<td>Response rate</td>
<td>98% at 24 h</td>
<td>76% at 1 mo</td>
</tr>
<tr>
<td>Potassium level maintained (mEq/L)</td>
<td>4.5 (5-10 g QD)</td>
<td>4.6 (17.5 g BID)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Safety</th>
<th>Sodium Zirconium Cyclosilicate</th>
<th>Patiromer Sorbitex Calcium</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI adverse event rate</td>
<td>3.5%</td>
<td>19%</td>
</tr>
<tr>
<td>Open-label phase</td>
<td>6% vs 14% for placebo</td>
<td>13% vs 6% for placebo</td>
</tr>
<tr>
<td>Randomized phase</td>
<td>None</td>
<td>10 g for every 21 g of polymer</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>None</td>
<td>10 g for every 21 g of polymer</td>
</tr>
<tr>
<td>Calcium</td>
<td>No impact</td>
<td>~ 4 g calcium load but small amounts absorbed, may bind PO₄³⁻</td>
</tr>
<tr>
<td>Magnesium</td>
<td>No hypomagnesia</td>
<td>24% with Mg²⁺ &lt; 1.8 mg/dL</td>
</tr>
<tr>
<td>Fluoride</td>
<td>No impact</td>
<td>Increased serum fluoride</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>↑ 2.3 mEq/L in 15 d</td>
<td>No significant changes</td>
</tr>
<tr>
<td>Blood urea nitrogen</td>
<td>↓ Potentially due to binding of ammonium</td>
<td>No significant changes</td>
</tr>
<tr>
<td>Drug-drug interaction</td>
<td>None</td>
<td>Valsartan and rosiglitazone</td>
</tr>
<tr>
<td>Sodium absorption</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

BID, twice daily; GI, gastrointestinal; QD, daily; TID, three times per day.


potentially life-saving RAAS inhibitors and, in worse cases, the use of sodium polystyrene sulfonate with its associated high incidence of adverse reactions. Newer options will allow for effective treatment of hyperkalemia while maintaining patients on prescribed RAAS inhibitors. The introduction of patiromer to the marketplace provides one new option to treat hyperkalemia that appears to be better tolerated then sodium polystyrene sulfonate, but it has a black box warning not to be given within 6 hours of other medications. The anticipated introduction of ZS-9 to the marketplace will provide another new option for treating hyperkalemia. It appears to be well tolerated, with a more rapid onset of action; with its high
specificity for potassium the timing of its use is not limited by concomitant medication. The introduction of these new options for treating hyperkalemia is expected to lead to treatment at the time of diagnosis by cardiologists.

References

MAIN POINTS
• Hyperkalemia (defined as a serum potassium level > 5 mmol/L) is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and increased mortality. It is likely to become more common clinically because angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are increasingly being used in higher doses.
• Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist.
• Sodium polystyrene sulfonate use is associated with a variety of shortcomings, including the high dose of sorbitol leading to gastrointestinal intolerance, sodium loading, and the resultant volume overload, making it a poor candidate for the chronic treatment of hyperkalemia.
• Patiromer, a recent entrant into the marketplace, is indicated for the treatment of hyperkalemia. Its safety and effectiveness were demonstrated in a series of modest-sized clinical trials.
• Sodium zirconium cyclosilicate is a highly selective cation exchanger that entraps potassium in the intestinal tract in exchange for sodium and hydrogen; US Food and Drug Administration approval is pending.

S20 • Vol. 17 Suppl. 1 • 2016 • Reviews in Cardiovascular Medicine


